Integrum AB Series B (INTEG-B) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.018x

Based on the latest financial reports, Integrum AB Series B (INTEG-B) has a cash flow conversion efficiency ratio of -0.018x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-3.10 Million ≈ $-333.07K USD) by net assets (Skr172.01 Million ≈ $18.51 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Integrum AB Series B balance sheet independence to measure how much of total assets are equity-financed.

Integrum AB Series B - Cash Flow Conversion Efficiency Trend (2014–2025)

This chart illustrates how Integrum AB Series B's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Integrum AB Series B cash earnings quality to evaluate the quality of earnings relative to operating cash generation.

Integrum AB Series B Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Integrum AB Series B ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
CHAR Technologies Ltd V:YES	-0.259x
Tevogen Bio Holdings Inc. NASDAQ:TVGN	0.278x
Bangkok Sheet Metal Public Company Limited BK:BM	0.033x
AVTECH Sweden AB Series B ST:AVT-B	0.012x
Handok Clean Tech Co. Ltd KQ:256150	0.048x
Juggernaut Exploration Ltd V:JUGR	-0.036x
Pili International Multimedia Co Ltd TWO:8450	-0.127x
OCB Bhd KLSE:5533	0.049x

Annual Cash Flow Conversion Efficiency for Integrum AB Series B (2014–2025)

The table below shows the annual cash flow conversion efficiency of Integrum AB Series B from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see Integrum AB Series B market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr172.01 Million ≈ $18.51 Million	Skr-41.02 Million ≈ $-4.41 Million	-0.239x	-12.53%
2024-12-31	Skr177.88 Million ≈ $19.14 Million	Skr-37.70 Million ≈ $-4.06 Million	-0.212x	-137.47%
2023-12-31	Skr142.79 Million ≈ $15.37 Million	Skr-12.74 Million ≈ $-1.37 Million	-0.089x	+48.96%
2022-12-31	Skr143.53 Million ≈ $15.45 Million	Skr-25.10 Million ≈ $-2.70 Million	-0.175x	-37.73%
2021-12-31	Skr159.74 Million ≈ $17.19 Million	Skr-20.28 Million ≈ $-2.18 Million	-0.127x	+46.48%
2020-12-31	Skr24.29 Million ≈ $2.61 Million	Skr-5.76 Million ≈ $-620.14K	-0.237x	+69.94%
2019-12-31	Skr23.73 Million ≈ $2.55 Million	Skr-18.72 Million ≈ $-2.01 Million	-0.789x	+49.90%
2018-12-31	Skr16.05 Million ≈ $1.73 Million	Skr-25.28 Million ≈ $-2.72 Million	-1.575x	-62.44%
2017-12-31	Skr18.00 Million ≈ $1.94 Million	Skr-17.45 Million ≈ $-1.88 Million	-0.969x	-238.90%
2016-12-31	Skr10.53 Million ≈ $1.13 Million	Skr-3.01 Million ≈ $-324.30K	-0.286x	+88.15%
2015-12-31	Skr1.14 Million ≈ $122.14K	Skr-2.74 Million ≈ $-294.76K	-2.413x	-312.76%
2014-12-31	Skr1.13 Million ≈ $122.04K	Skr-663.00K ≈ $-71.35K	-0.585x	--

About Integrum AB Series B

ST:INTEG-B Sweden Medical Devices

Market Cap

$23.78 Million

Skr220.98 Million SEK

Market Cap Rank

#24499 Global

#488 in Sweden

Share Price

Skr8.49

Change (1 day)

-3.30%

52-Week Range

Skr6.96 - Skr43.10

All Time High

Skr102.00